|
1
|
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
|
J Clin Oncol
|
2011
|
6.16
|
|
2
|
Controlling tumor growth by modulating endogenous production of reactive oxygen species.
|
Cancer Res
|
2005
|
3.12
|
|
3
|
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.
|
Pharm Res
|
2011
|
0.96
|
|
4
|
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2011
|
0.90
|
|
5
|
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
|
Invest New Drugs
|
2010
|
0.85
|
|
6
|
An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2013
|
0.81
|
|
7
|
Nutritional status is superior to the ECOG performance status in predicting the dose-intensity of the GEMOX chemotherapy regimen in patients with advanced cancer.
|
Nutr Cancer
|
2013
|
0.78
|
|
8
|
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
|
Expert Opin Drug Saf
|
2014
|
0.76
|
|
9
|
An original administration of ifosfamide given once every other week: a clinical and pharmacological study.
|
Anticancer Drugs
|
2008
|
0.76
|
|
10
|
Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.
|
Expert Opin Investig Drugs
|
2015
|
0.76
|